{"schema_version":"secwatch.filing_event.v1","accession":"0001703057-23-000047","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2023-11-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.105273+00:00","generated_at":"2026-06-07T21:04:55.494716+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AbCellera cuts ~10% of workforce in reorganization; estimates $2.5M cash cost","bullets":["Reduction impacts approximately 10% of employees to focus on clinical development and strategic partnerships.","Estimated $2.5 million in cash expenses from the workforce reduction.","Company reports over $1 billion in available liquidity, sufficient for strategy beyond 3 years.","Reorganization aims to increase operational efficiency and prioritize internal drug development."],"urls":{"canonical":"https://secwatch.observer/filing/0001703057-23-000047","json":"https://secwatch.observer/filing/0001703057-23-000047.json","markdown":"https://secwatch.observer/filing/0001703057-23-000047.md","text":"https://secwatch.observer/filing/0001703057-23-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000047/0001703057-23-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000170305723000047/abcl-20231128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T21:04:55.494716+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}